News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Astellas Pharma Inc. (JOBS) Scraps Agreement with Neurosearch A/S on ACR16
March 4, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, March 3 (Reuters) - Astellas Pharma Inc, Japan's second-biggest drugmaker, said on Tuesday that it has scrapped its licensing agreement with a Neurosearch A/S unit on a drug to treat schizophrenia.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Asia
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Obesity
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
January 30, 2026
·
2 min read
·
Tristan Manalac
Insights
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
January 29, 2026
·
3 min read
·
Jennifer Smith-Parker
IPO
Eikon, Veradermics, Announce IPO Targets as Cautious Optimism Propels Biotech Market
January 29, 2026
·
3 min read
·
Tristan Manalac
China
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
January 29, 2026
·
1 min read
·
Tristan Manalac
